Enriched variations in TEKT4 and breast cancer resistance to paclitaxel

Nature Communications

Volumn 5, Issue , 2014, Pages

  Jiang, Yi Zhou ^a   Yu, Ke Da ^a   Peng, Wen Ting ^a   Di, Gen Hong ^a   Wu, Jiong ^a   Liu, Guang Yu ^a   Shao, Zhi Ming ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; CYCLIN DEPENDENT KINASE 1; DOCETAXEL; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; PACLITAXEL; PROTEIN; TEKTIN 1; TEKTIN 2; TEKTIN 3; TEKTIN4; TUBULIN; UNCLASSIFIED DRUG; VINBLASTINE; ANTINEOPLASTIC AGENT; MICROTUBULE PROTEIN; TEKTINS;

CANCER; CHEMOTHERAPY; DRUG; DRUG RESISTANCE; SURVIVAL; TUMOR; WOMENS HEALTH;

ADULT; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SIZE; CELL ADHESION; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL INVASION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CENTRIOLE; COLONY FORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EUKARYOTIC FLAGELLUM; EXOME; FEMALE; FLAGELLUM; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; KINETOSOME; MAJOR CLINICAL STUDY; MICROTUBULE; MITOSIS; OVERALL SURVIVAL; PROTEIN STRUCTURE; PYROSEQUENCING; SOMATIC MUTATION; WESTERN BLOTTING; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COHORT ANALYSIS; DRUG RESISTANCE; GENETICS; METABOLISM; MIDDLE AGED; PROGNOSIS; TUMOR CELL LINE;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC VARIATION; HUMANS; MICROTUBULE PROTEINS; MICROTUBULES; MIDDLE AGED; PACLITAXEL; PROGNOSIS;

EID: 84900851474     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4802     Document Type: Article

References (54)

1. Honma, K. et al. RPN2 gene confers docetaxel resistance in breast cancer. Nat. Med. 14, 939-948 (2008).
2. Engels, F. K., Sparreboom, A., Mathot, R. A. & Verweij, J. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br. J. Cancer 93, 173-177 (2005). (Pubitemid 41133202)
3. Giordano, S. H. et al. Decline in the use of anthracyclines for breast cancer. J. Clin. Oncol. 30, 2232-2239 (2012).
4. Jones, S. E. et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J. Clin. Oncol. 23, 5542-5551 (2005).
5. Gottesman, M. M., Fojo, T. & Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58 (2002). (Pubitemid 37328807)
6. Childs, S., Yeh, R. L., Hui, D. & Ling, V. Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. Cancer Res. 58, 4160-4167 (1998). (Pubitemid 28440574)
7. Hopper-Borge, E. et al. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res. 64, 4927-4930 (2004). (Pubitemid 38924539)
8. Kavallaris, M. Microtubules and resistance to tubulin-binding agents. Nat. Rev. Cancer 10, 194-204 (2010).
9. Martello, L. A. et al. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res. 63, 1207-1213 (2003). (Pubitemid 36355832)
10. Poruchynsky, M. S. et al. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism. Biochem. Pharmacol. 62, 1469-1480 (2001). (Pubitemid 33145290)
11. Balko, J. M. et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat. Med. 18, 1052-1059 (2012).
12. Ignatiadis, M. et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J. Clin. Oncol. 30, 1996-2004 (2012).
13. Modlich, O. et al. Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. Clin. Cancer Res. 10, 6418-6431 (2004). (Pubitemid 39346536)
14. Buchholz, T. A. et al. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J. 8, 461-468 (2002).
15. Lee, S. C. et al. Chemotherapy-induced tumor gene expression changes in human breast cancers. Pharmacogenet. Genomics 19, 181-192 (2009).
16. Balko, J. M. et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 4, 232-245 (2014).
17. Yu, K. D. et al. Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancer. Oncologist 17, 792-800 (2012).
18. Chen, X. S. et al. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann. Oncol. 21, 961-967 (2010).
19. Kennecke, H. et al. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 28, 3271-3277 (2010).
20. Voduc, K. D. et al. Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 28, 1684-1691 (2010).
21. Setter, P. W. et al. Tektin interactions and a model for molecular functions. Exp. Cell Res. 312, 2880-2896 (2006).
22. Amos, L. A. The tektin family of microtubule-stabilizing proteins. Genome Biol. 9, 229 (2008).
23. Sakurikar, N., Eichhorn, J. M. & Chambers, T. C. Cyclin-dependent kinase-1 (Cdk1)/cyclin B1 dictates cell fate after mitotic arrest via phosphoregulation of antiapoptotic Bcl-2 proteins. J. Biol. Chem. 287, 39193-39204 (2012).
24. Palazzo, A., Ackerman, B. & Gundersen, G. G. Cell biology: tubulin acetylation and cell motility. Nature 421, 230 (2003). (Pubitemid 36139118)
25. Zach, F. et al. The retinitis pigmentosa 28 protein FAM161A is a novel ciliary protein involved in intermolecular protein interaction and microtubule association. Hum. Mol. Genet. 21, 4573-4586 (2012).
26. Aparicio, S. & Caldas, C. The implications of clonal genome evolution for cancer medicine. N. Engl. J. Med. 368, 842-851 (2013).
27. Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399 (2012).
28. Stephens, P. J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404 (2012).
29. Schuh, A. et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood 120, 4191-4196 (2012).
30. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
31. Iida, H. et al. Tektin 4 is located on outer dense fibers, not associated with axonemal tubulins of flagella in rodent spermatozoa. Mol. Reprod. Dev. 73, 929-936 (2006). (Pubitemid 43825298)
32. Nowak, M. A. & Sigmund, K. Evolutionary dynamics of biological games. Science 303, 793-799 (2004). (Pubitemid 38174649)
33. Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306-313 (2012).
34. Landau, D. A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 (2013).
35. Comino-Mendez, I. et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat. Genet. 43, 663-667 (2011).
36. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576 (2012).
37. Tuupanen, S. et al. Allelic imbalance at rs6983267 suggests selection of the risk allele in somatic colorectal tumor evolution. Cancer Res. 68, 14-17 (2008). (Pubitemid 351380099)
38. Canzian, F. et al. Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res. 56, 3331-3337 (1996). (Pubitemid 26242985)
39. Yu, K. D. et al. Genetic variants in oxidative stress-related genes predict chemoresistance in primary breast cancer: a prospective observational study and validation. Cancer Res. 72, 408-419 (2012).
40. Goldhirsch, A. et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 22, 1736-1747 (2011).
41. Yan, X. J. et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat. Genet. 43, 309-315 (2011).
42. Li, Y. et al. Resequencing of 200 human exomes identifies an excess of lowfrequency non-synonymous coding variants. Nat. Genet. 42, 969-972 (2010).
43. Zang, Z. J. et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 44, 570-574 (2012).
44. Li, R. et al. SOAP2: an improved ultrafast tool for short read alignment. Bioinformatics 25, 1966-1967 (2009).
45. Amos-Landgraf, J. M. et al. A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer. Proc. Natl Acad. Sci. USA 104, 4036-4041 (2007). (Pubitemid 47181574)
46. Lai, L. A. et al. Deletion at fragile sites is a common and early event in Barretts esophagus. Mol. Cancer Res. 8, 1084-1094 (2010).
47. Chen, A. X. et al. Germline genetic variants disturbing the Let-7/LIN28 doublenegative feedback loop alter breast cancer susceptibility. PLoS Genet. 7, e1002259 (2011).
48. Zhang, L. et al. The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene 46, 5347-5358 (2013).
49. Cheng, G. Z. et al. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 67, 1979-1987 (2007). (Pubitemid 46424214)
50. Franken, N. A. et al. Clonogenic assay of cells in vitro. Nat. Protoc. 1, 2315-2319 (2006).
51. Hari, M. et al. Paclitaxel-resistant cells have a mutation in the paclitaxelbinding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol. Cancer Ther. 5, 270-278 (2006).
52. Wang, L. et al. Abnormal expression of GADD45B in human colorectal carcinoma. J. Transl. Med. 10, 215 (2012).
53. Lin, B. et al. WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence. Clin. Cancer Res. 14, 1397-1406 (2008). (Pubitemid 351413921)
54. Halvorsen, O. J. et al. Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer. Clin. Cancer Res. 13, 892-897 (2007). (Pubitemid 46340364)